Acetylcholine inhibits hypoxia-induced tumor necrosis factor-α production via regulation of MAPKs phosphorylation in cardiomyocytes

Journal of Cellular Physiology

Volumn 226, Issue 4, 2011, Pages 1052-1059

  Li, Dong Ling ^a   Liu, Jin Jun ^a   Liu, Bing Hang ^a   Hu, Hao ^a   Sun, Lei ^a   Miao, Yi ^a   Xu, Hai Fei ^a   Yu, Xiao Jiang ^a   Ma, Xin ^a   Ren, Jun ^b   Zang, Wei Jin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATROPINE; CASPASE 3; HEXAMETHONIUM; MESSENGER RNA; METHOCTRAMINE; METHYLLYCACONITINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCARINIC M2 RECEPTOR; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL HYPOXIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EMBRYO; HEART MUSCLE CELL; HEART PROTECTION; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ANIMALS; CASPASE 3; CELL DEATH; CELL HYPOXIA; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; PHOSPHORYLATION; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, MUSCARINIC M2; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79251518044     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22424     Document Type: Article

References (34)

1. Armstrong SC. 2004. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61:427-436.
2. Bassi R, Heads R, Marber MS, Clark JE. 2008. Targeting p38-MAPK in the ischaemic heart: Kill or cure? Curr Opin Pharmacol 8:141-146.
3. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. 2002. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: A current perspective. Cardiovasc Res 53:822-830.
4. Cai B, Chen F, Ji Y, Kiss L, de Jonge WJ, Conejero-Goldberg C, Szabo C, Deitch EA, Ulloa L. 2009. Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation. J Cell Mol Med 13:3774-3785.
5. Critz SD, Cohen MV, Downey JM. 2005. Mechanisms of acetylcholine- and bradykinin-induced preconditioning. Vascul Pharmacol 42:201-209.
6. de Couto PA, Borda E, Ganzinelli S, Passafaro D, Sterin-Borda L. 2009. Cholinoceptor modulation on nitric oxide regulates prostaglandin E(2) and metalloproteinase-3 production in experimentally induced inflammation of rat dental pulp. J Endod 35:529-536.
7. Dhingra S, Sharma AK, Arora RC, Slezak J, Singal PK. 2009. IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. Cardiovasc Res 82:59-66.
8. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. 2008. Tumor necrosis factor-alpha and mortality in heart failure: A community study. Circulation 118:625-631.
9. Dvorakova M, Lips KS, Bruggmann D, Slavikova J, Kuncova J, Kummer W. 2005. Developmental changes in the expression of nicotinic acetylcholine receptor alpha-subunits in the rat heart. Cell Tissue Res 319:201-209.
10. Esumi K, Nishida M, Shaw D, Smith TW, Marsh JD. 1991. NADH measurements in adult rat myocytes during simulated ischemia. Am J Physiol 260:H1743-H1752.
11. Fildes JE, Shaw SM, Yonan N, Williams SG. 2009. The immune system and chronic heart failure: Is the heart in control? J Am Coll Cardiol 53:1013-1020.
12. Freeling J, Wattier K, LaCroix C, Li YF. 2008. Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload. Exp Physiol 93:75-82.
13. Kakinuma Y, Ando M, Kuwabara M, Katare RG, Okudela K, Kobayashi M, Sato T. 2005. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha. FEBS Lett 579:2111-2118.
14. Kim MH, Kim MO, Heo JS, Kim JS, Han HJ. 2008. Acetylcholine inhibits long-term hypoxia-induced apoptosis by suppressing the oxidative stress-mediated MAPKs activation as well as regulation of Bcl-2, c-IAPs, and caspase-3 in mouse embryonic stem cells. Apoptosis 13:295-304.
15. Kimura H, Shintani-Ishida K, Nakajima M, Liu S, Matsumoto K, Yoshida K. 2006. Ischemic preconditioning or p38 MAP kinase inhibition attenuates myocardial TNF alpha production and mitochondria damage in brief myocardial ischemia. Life Sci 78:1901-1910.
16. Krejci A, Tucek S. 2002. Quantitation of mRNAs for M(1) to M(5) subtypes of muscarinic receptors in rat heart and brain cortex. Mol Pharmacol 61:1267-1272.
17. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. 2004. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109:120-124.
18. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, Wang Y. 2005. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111:2494-2502.
19. Liu H, McPherson BC, Zhu X, Da CM, Jeevanandam V, Yao Z. 2001. Role of nitric oxide and protein kinase C in ACh-induced cardioprotection. Am J Physiol Heart Circ Physiol 281:H191-H197.
20. Lu J, Zang WJ, Yu XJ, Jia B, Chorvatova A, Sun L. 2006. Effects of postconditioning of adenosine and acetylcholine on the ischemic isolated rat ventricular myocytes. Eur J Pharmacol 549:133-139.
21. Meldrum DR. 1998. Tumor necrosis factor in the heart. Am J Physiol 274:R577-R595.
22. Nian M, Lee P, Khaper N, Liu P. 2004. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543-1553.
23. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. 2008. Parasympathetic nervous system and heart failure: Pathophysiology and potential implications for therapy. Circulation 118:863-871.
24. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, Srivastava D, Bhatnagar A, Srivastava SK. 2006. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 114:1838-1846.
25. Sack M. 2002. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther 94:123-135.
26. Schulz R, Aker S, Belosjorow S, Heusch G. 2004. TNF alpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 99:8-11.
27. Schwartz PJ, de Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. 2008. Long term vagal stimulation in patients with advanced heart failure: First experience in man. Eur J Heart Fail 10:884-891.
28. Shames BD, Barton HH, Reznikov LL, Cairns CB, Banerjee A, Harken AH, Meng X. 2002. Ischemia alone is sufficient to induce TNF-alpha mRNA and peptide in the myocardium. Shock 17:114-119.
29. Sroka K. 2004. On the genesis of myocardial ischemia. Z Kardiol 93:768-783.
30. Sucher R, Gehwolf P, Kaier T, Hermann M, Maglione M, Oberhuber R, Ratschiller T, Kuznetsov AV, Bösch F, Kozlov AV, Ashraf MI, Schneeberger S, Brandacher G, Öllinger R, Margreiter R, Troppmair J. 2009. Intracellular signaling pathways control mitochondrial events associated with the development of ischemia/reperfusion-associated damage. Transpl Int 22:922-930.
31. Tracey KJ. 2007. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117:289-296.
32. Ulloa L. 2005. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 4:673-684.
33. WHO. 2008. World health statistics 2008. pp. 29-30.
34. Yin H, Zhang J, Lin H, Wang R, Qiao Y, Wang B, Liu F. 2008. p38 mitogen-activated protein kinase inhibition decreases TNF-alpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia. Inflammation 31:65-73.